Free tool
Cell therapy stocks
We cover 4 companies grouped under the Cell therapy theme. The median market value in the group is $1.13B. Across the group, the median move over the past trading day is +0.95%. Price change over the past year runs from −44.4% to +5.4% across the middle 80 percent of the group, with a median of −21.4%.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
4 of 86 companies match these filters.Clear filters
| Ticker | Company | Price | 1M return | YTD return | 1Y return | Next report |
|---|---|---|---|---|---|---|
| MSB.AX | Mesoblast Limited | 2.40 AUD | +16.26% | −13.54% | −3.82% | Aug 27, 2026 |
| MESO | Mesoblast Limited | $17.19 | +18.06% | −5.34% | +9.42% | Aug 27, 2026 |
| SVA.TO | Sernova Biotherapeutics Inc | 0.11 CAD | −8.33% | −15.38% | −38.89% | Sep 10, 2026 |
| PSH0.DE | Sernova Biotherapeutics Inc | 0.06 EUR | −9.73% | −26.71% | −46.78% | Sep 10, 2026 |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.